ALLO Stock Cash Flow Statements

Allogene Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Allogene Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31

cash flows from operating activities:
net income	-50,943,000	-59,733,000	-59,939,000	-66,293,000	-66,358,000	-65,000,000	-89,257,000	-61,315,000	-77,989,000	-98,704,000	-94,847,000	-83,148,000	-74,787,000	-79,850,000	-74,868,000	-78,186,000	-70,936,000	-33,015,000	-68,570,000	-66,197,000	-60,974,000	-54,480,000	-61,030,000	-50,735,000	-41,243,000	-31,586,000	-30,509,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	8,685,000	12,175,000	12,873,000	13,387,000	13,559,000	11,924,000	15,233,000	15,354,000	16,594,000	18,770,000	17,246,000	21,148,000	22,891,000	22,315,000	22,036,000	20,856,000	21,134,000	16,792,000	16,453,000	17,823,000	16,770,000	14,215,000	13,874,000	12,835,000	11,487,000	7,867,000	5,871,000
depreciation and amortization	3,106,000	3,099,000	3,233,000	3,207,000	3,644,000	3,555,000	3,477,000	3,572,000	3,643,000	3,507,000	3,068,000	3,860,000	3,675,000	3,692,000	4,242,000	2,330,000	1,964,000	1,918,000	1,844,000	1,810,000	1,888,000	1,893,000	1,704,000	1,177,000	999,000	544,000	397,000
net amortization/accretion on investment securities	-1,171,000	-1,306,000			-2,201,000	-2,797,000	-3,299,000	-2,944,000	-1,074,000	508,000	156,000	495,000	908,000	1,332,000	1,594,000	1,615,000	1,835,000	1,911,000	1,813,000	1,417,000	227,000	-207,000	-460,000	-851,000	-1,062,000	-1,223,000	-1,161,000
impairment of long-lived assets				10,728,000
non-cash rent expense	1,147,000	1,130,000	1,116,000	4,299,000	-96,000	-55,000	138,000	147,000	150,000	207,000	240,000	553,000	1,174,000	466,000	-11,000	228,000	387,000	2,007,000	2,715,000	180,000	342,000	718,000	1,950,000	3,279,000	273,000	1,275,000	1,168,000
non-cash collaboration revenue - related party			0	0	0	-14,000
share of income from equity method investments					-375,000	929,000
changes in operating assets and liabilities:
deposit placed in escrow	-1,843,000	-868,000	1,547,000	-891,000
prepaid expenses and other current assets	1,865,000	-623,000	1,802,000	-341,000	-1,867,000	-86,000	-2,469,000	2,190,000	102,000	1,263,000	5,328,000	5,704,000	-1,842,000	-6,673,000	5,352,000	-4,908,000	2,015,000	740,000	-3,834,000	-3,459,000	1,564,000	2,552,000	-5,531,000	607,000	1,371,000	-1,892,000	-5,466,000
other long-term assets	-1,928,000	425,000	688,000	1,469,000	677,000	1,445,000	-1,034,000	-366,000	-100,000	45,000	-123,000	-408,000	311,000	-3,114,000	345,000	-331,000	139,000	-799,000	-1,941,000	-483,000	2,515,000	-57,000	-1,511,000	-870,000	-1,805,000	-188,000	1,224,000
accounts payable	-422,000	-336,000	34,000	-7,227,000	6,808,000	-118,000	-302,000	-3,967,000	-4,290,000	1,057,000	2,938,000	1,013,000	1,422,000	-505,000	-2,044,000	189,000	-3,064,000	4,152,000	-1,066,000	2,184,000	541,000	-1,044,000	2,152,000	-4,469,000	1,680,000	-348,000	5,717,000
accrued and other current liabilities	1,735,000	-5,223,000	2,880,000	2,528,000	-980,000	-5,690,000	286,000	-12,716,000	-76,000	5,686,000	3,137,000	1,946,000	5,714,000	-9,048,000	-2,768,000	8,890,000	1,844,000	-4,314,000	2,551,000	9,346,000	10,742,000	-3,913,000	-1,159,000	7,617,000	3,988,000	-4,095,000	-557,000
operating lease liabilities	-1,926,000	-1,833,000	-1,776,000
other long-term liabilities	283,000	164,000	95,000	115,000	41,000	8,000	-528,000	-37,000	13,000	-59,000	-464,000	-521,000	-936,000	-635,000	-1,050,000	-530,000	2,914,000	-292,000	290,000	-370,000	-487,000	-701,000	-434,000	-709,000	-571,000	-711,000
net cash from operating activities	-39,030,000	-52,929,000	-36,698,000	-44,115,000	-63,588,000	-55,899,000	-53,707,000	-55,530,000	-61,857,000	-66,639,000	-62,096,000	-47,655,000	-42,531,000	-68,237,000	-45,436,000	-48,878,000	-41,170,000	-49,328,000	-9,975,000	-37,588,000	-26,721,000	-40,809,000			-24,892,000	-30,256,000	-21,481,000
capex	-44,000	-99,000	-257,000	-429,000	0	-8,000	-181,000	-12,000	-288,000	-1,035,000	-1,692,000	-223,000	-1,374,000	-1,902,000	-736,000	-3,347,000	-10,902,000	-6,461,000	-17,404,000	-20,247,000	-16,054,000	-12,253,000			-7,856,000	-10,423,000	-1,321,000
free cash flows	-39,074,000	-53,028,000	-36,955,000	-44,544,000	-63,588,000	-55,907,000	-53,888,000	-55,542,000	-62,145,000	-67,674,000	-63,788,000	-47,878,000	-43,905,000	-70,139,000	-46,172,000	-52,225,000	-52,072,000	-55,789,000	-27,379,000	-57,835,000	-42,775,000	-53,062,000			-32,748,000	-40,679,000	-22,802,000
cash flows from investing activities:
purchases of property and equipment	-44,000	-99,000	-257,000	-429,000	0	-8,000	-181,000	-12,000	-288,000	-1,035,000	-1,692,000	-223,000	-1,374,000	-1,902,000	-736,000	-3,347,000	-10,902,000	-6,461,000	-17,404,000	-20,247,000	-16,054,000	-12,253,000	-14,112,000	-18,400,000	-7,856,000	-10,423,000	-1,321,000
proceeds from maturities of investments	53,800,000	56,500,000	102,165,000	109,801,000	117,221,000	103,272,000	136,344,000	165,158,000	152,868,000	143,441,000	99,080,000	74,582,000	117,117,000	68,680,000	82,540,000	161,772,000	215,833,000	268,249,000	221,850,000	150,144,000	101,372,000	120,261,000	116,813,000	158,350,000
purchase of investments	-9,921,000	-50,225,000	-46,974,000	-190,762,000	-42,608,000	-81,131,000	-68,702,000	-199,413,000	-135,420,000	-35,094,000	-47,791,000	-49,454,000	-61,709,000	-89,155,000	-50,782,000	-145,422,000	-180,327,000	-149,052,000	-182,158,000	-213,252,000	-519,166,000	-123,015,000	-89,697,000	-61,175,000	-49,359,000	-52,397,000	-333,908,000
net cash from investing activities	43,835,000	6,176,000	54,934,000	-75,992,000	74,613,000	22,133,000	67,461,000	-34,267,000	17,160,000	112,935,000	49,597,000	24,905,000	54,034,000	-22,377,000	29,250,000	13,013,000	24,594,000	96,798,000	22,210,000	-83,355,000	-428,971,000	-15,007,000	7,929,000	78,775,000	44,492,000	32,888,000	-313,388,000
cash flows from financing activities:
proceeds from issuance of common stock from atm offering, net of commissions and issuance costs	1,514,000	10,002,000	5,743,000	0			0	3,194,000												0
proceeds from issuance of common stock from registered offering, net of commissions and issuance costs				0
proceeds from cirm award	3,558,000	3,350,000	0	0
proceeds from issuance of common stock upon exercise of stock options				0	19,000	794,000		326,000				135,000	25,000	283,000		750,000	3,214,000	4,060,000		2,414,000
proceeds from issuance of common stock under the employee stock purchase plan	0	638,000	0	679,000	0	856,000	0	765,000	0	1,731,000	0	931,000	-1,000	1,531,000	0	1,633,000	0	1,984,000	-1,000	1,406,000	0	1,438,000
net cash from financing activities	5,072,000	13,990,000	5,743,000	679,000	108,603,000	1,650,000	155,000	4,285,000	89,524,000	1,731,000	46,000	1,066,000	24,000	1,814,000	322,000	2,383,000	3,214,000	6,044,000	12,978,000	3,852,000	600,175,000	16,586,000	56,474,000	1,566,000	236,000	684,000	344,522,000
net change in cash and cash equivalents and restricted cash	9,877,000	-32,763,000		-119,428,000	119,628,000	-32,116,000		-85,512,000	44,827,000	48,027,000
cash and cash equivalents and restricted cash — beginning of period	0	85,510,000		0	0	93,447,000		0	0	72,196,000
cash and cash equivalents and restricted cash — end of period	9,877,000	52,747,000		-119,428,000	119,628,000	61,331,000		-85,512,000	44,827,000	120,223,000
non-cash operating activities:
right-of-use asset obtained in exchange for lease liability			0	0	0	2,409,000					0	0															7,693,000
property and equipment purchases in accounts payable and accrued liabilities																					4,090,000	4,208,000
non-cash deferred revenue and other long-term liabilities	0	3,079,000				3,079,000
supplemental disclosure:
cash paid for amounts included in the measurement of lease liabilities	-3,291,000	-3,227,000	-3,197,000	-3,135,000	-3,105,000	-3,068,000	-3,036,000	-3,024,000	-3,024,000	-2,965,000	-2,935,000	-2,622,000	-2,003,000	-1,980,000	-1,955,000	-1,626,000	-1,466,000	-966,000	-10,480,000	1,420,000	1,420,000	1,396,000	-5,745,000	1,026,000	765,000	391,000
impairment of long-lived asset
impairment of equity investment and equity method investment
income tax expense
proceeds from sales of investments			0				0	0	0	5,623,000									-78,000	0
proceeds from issuance of common stock from public offering, net of commissions and issuance costs																				32,000
proceeds from issuance of common stock and upon exercise of stock options																						303,000	2,255,000	467,000			-5,000
net increase in cash, cash equivalents and restricted cash																							14,136,000	48,406,000	19,836,000	3,316,000	9,653,000
cash, cash equivalents and restricted cash — beginning of period											0	0	0	183,606,000	0	0	0	192,800,000	0	0	0	179,425,000	0	0	0	93,731,000
cash, cash equivalents and restricted cash — end of period											-12,453,000	-21,684,000	11,527,000	94,806,000	-15,864,000	-33,482,000	-13,362,000	246,314,000	25,213,000	-117,091,000	144,483,000	140,195,000	14,136,000	48,406,000	19,836,000	97,047,000	9,653,000
non-cash operating, investing and financing activities:
property and equipment purchases in accounts payable and accrued and other current liabilities													-683,000	725,000	613,000	-594,000	-6,593,000	8,299,000	658,000
amortization/accretion on investment securities
impairment of equity method investment
share of gain/income from equity method investments
non-cash deferred revenue included in other long-term liabilities				0
deferred revenue							646,000	7,000	-44,000	-612,000	-4,000	53,000	430,000	-17,000	58,000	60,000	66,000	-38,753,000
purchase of stock in equity method investment															-1,772,000	0	0	-15,938,000
capitalized cloud computing costs included in accounts payable and accrued and other current liabilities													209,000	111,000				277,000
cash received for amounts related to tenant improvement allowances from lessors
share of income from, and impairment of, equity method investment
non-cash investing activities:
cash received for amounts related to tenant improvement allowances												0	0	325,000		0	0	1,111,000		704,000	1,085,000	532,000
share of income from equity method investment									1,214,000	1,693,000		1,650,000	-1,491,000	3,800,000
amortization of other intangible assets acquired																			0	0	0	151,000	151,000	151,000	150,000	151,000	150,000
share of losses from equity method investments															1,678,000	909,000	532,000	325,000	778,000	161,000	151,000	64,000
net change in cash, cash equivalents and restricted cash												-21,684,000	11,527,000	-88,800,000		-33,482,000	-13,362,000	53,514,000		-117,091,000	144,483,000	-39,230,000
income tax benefit
deferred offering costs included in accounts payable and accrued and other current liabilities																											-1,032,000
proceeds (loss) from sales of investments
acquired in-process research and development																											0
change in fair value of convertible notes payable																											1,796,000
debt issuance costs on convertible notes payable																											0
other
cash paid for acquisition of assets																											0
proceeds from issuance of convertible preferred stock, net of issuance costs																											-1,000
proceeds from issuance of convertible notes, net of issuance costs																											0
proceeds from early exercise of stock options
proceeds from issuance of common stock, net of commissions and issuance costs																						14,845,000
common stock issued on conversion of convertible preferred stock
common stock issued on conversion of convertible notes payable
series a-1 convertible preferred stock issued in asset acquisition																											0
pp&e and other assets acquired in asset acquisition
benefit from income taxes
adjustments to reconcile net income to net cash (used in) operating activities:
acquired in process-research and development
deferred income taxes																								33,000	-159,000	-50,000
net cash (used in) operating activities
payments of deferred offering costs
proceeds from employee stock purchase plan																								1,099,000	0	684,000
non-cash investing and financing activities:
property and equipment purchase in accounts payable and accrued liabilities																								-7,096,000	8,533,000	5,134,000
subscriptions receivable from preferred shareholders
vesting of early exercised options
proceeds from sales or maturities of investments																										95,708,000
proceeds from issuance of common stock, net of issuance costs

We provide you with 20 years of cash flow statements for Allogene Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Allogene Therapeutics stock. Explore the full financial landscape of Allogene Therapeutics stock with our expertly curated income statements.

The information provided in this report about Allogene Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.